Obsidian
is a Massachusetts-based biotechnology company that researches and develops cell and gene therapies for the treatment of cancer... Read moreObsidian
is a Massachusetts-based biotechnology company that researches and develops cell and gene therapies for the treatment of cancer... Read more
News
Apr 19, 2026
MedCity News
Obsidian: Obsidian, Galera Merger Comes With $350M Infusion for Cancer Drug Trials
Apr 15, 2026
RTTNews
Obsidian: Galera Therapeutics, Obsidian Therapeutics Announces All-Stock Merger; Stock Up
Jun 02, 2025
StreetInsider
Press Release: Obsidian : Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meet
Jan 06, 2025
Business Wire
Press Release: Obsidian : Obsidian Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Nov 05, 2024
Business Wire
Press Release: Obsidian : Obsidian Therapeutics to Present Preclinical Data Supporting OBX-115 and cytoDRiVE Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
Sep 03, 2024
Business Wire
Press Release: Obsidian : Obsidian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OBX-115 for the Treatment of Advanced Melanoma
Jun 03, 2024
Business Wire
Press Release: Obsidian : Obsidian Therapeutics Announces Additional OBX-115 Safety and Efficacy Data in Oral Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 24, 2024
Business Wire
Press Release: Obsidian : Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Solid Tumors in Oral Presentation at the 2024 ASCO Annual Meeting
Apr 15, 2024
Citybizlist
Obsidian: Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer
Mar 05, 2024
Acrofan
Obsidian Therapeutics: Obsidian Therapeutics Announces Clinical & Preclinical Presentations at the American Association of Cancer Research Annual Meeting
Obsidian Competitors
1
2
3
4
5
6
7
8
9
10